<DOC>
	<DOCNO>NCT01395823</DOCNO>
	<brief_summary>A study report erythropoiesis-stimulating agent ( ESA ) dose 25D supplementation , one prospective clinical trial , small , single center study lack control arm . The investigator propose conduct double blind , randomize , placebo control clinical trial ergocalciferol supplementation confirm safety determine effect Erythropoietin ( EPO ) dosing , active D dosing , mineral metabolic parameter hemodialysis patient .</brief_summary>
	<brief_title>Safety Effects Supplementation With Ergocalciferol Erythropoietin Dosing Hemodialysis Patients</brief_title>
	<detailed_description />
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<criteria>1 . Patients treated thrice weekly incenter hemodialysis ( HD ) 90 day . 2 . Treated EPO least 90 day . The mode administration , intravenous ( IV ) subcutaneous ( SC ) , must remain 90 day prior enrollment . 3 . The method EPO prescribed ( per DCI Corporate local protocol per physician individualized basis ) must remain least 90 day prior enrollment respect ceiling total EPO dose administer per week , ceiling use , level hemoglobin ( Hgb ) EPO discontinue ( Hgb cutoff ) , Hgb cutoff use . 4 . The method IV Iron prescribe ( per DCI Corporate local protocol per physician individualized basis ) must remain least 90 day prior enrollment respect serum ferritin transferrin saturation ( TSAT ) target , specific ferritin TSAT target use 1 . Patients serum calcium â‰¥10.5 mg/dL least one occasion past 30 day . 2 . Patients serum phosphorus &gt; 8.0 mg/dL least one occasion past 30 day . 3 . Active infection define use IV antibiotic use within past 30 day . 4 . Current use immunosuppressant medication low dose corticosteroid ( prednisone &lt; 10 mg per day equivalent ) 5 . History hematological malignancy ( e.g . multiple myeloma , leukemia ) . 6 . Sickle cell disease ( sickle cell trait exclusion ) . 7 . Myelodysplasia require 1 blood transfusion past 3 month . 8 . Transfusion reason within past 30 day . 9 . Medical condition cause reduction absorption oral vitamin D include Crohn 's disease , celiac sprue , cystic fibrosis surgical removal part stomach intestine . 10 . Medications cause reduction absorption oral vitamin D include cholestyramine ( Questran , others ) , colestipol ( Colestid , others ) orlistat ( Xenical , Alli ) . 11 . Known allergy/adverse reaction ergocalciferol . 12 . Treated ergocalciferol and/or cholecalciferol ( except part multivitamin ) within last 3 month . 13 . Average Kt/V &lt; 1.3 past three monthly lab . There must least 2 monthly Kt/V value past three month . 14 . Skipped 3 dialysis treatment ( exclude plan missed treatment ) within past 3 month reason hospitalization . 15 . Life expectancy le 6 month . 16 . Kidney transplantation plan next 6 month . 17 . Switch peritoneal dialysis plan next 6 month . 18 . Pregnant plan become pregnant within next 6 month . A premenopausal woman must agree use contraception duration study . If woman menses 12 month , consider patient menopausal . 19 . Unable unwilling give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>